Strides Pharma Science Ltd · NSE:STAR

Strides Pharma Science — Q2 FY2022 Earnings Presentation

23 slides from Strides Pharma Science's earnings presentation, Nov 10, 2021

  1. Slide 1: Q2 and H1FY22 Earnings

    Q2 and H1FY22 Earnings November 10, 2021

  2. Slide 2: Strides reports muted Q2FY22 results

    Strides reports muted Q2FY22 results Successfully completes acquisition of Chestnut Ridge site along with ANDA’s from Endo We have reported an operational breakeven in Q2FY22 enabled by a bounce Revenues Mix back in other regulated markets, growing 27% QoQ. The performance in other regulated markets

  3. Slide 3: Financial performance in Q2 and H1 FY22

    Financial performance in Q2 and H1 FY22 Q2FY22 Q1FY22 Q2FY21 QoQ% YoY% H1FY22 H1FY21 YoY % REVENUES ₹7,360m ₹6,919m ₹7,971m 6% - 8% ₹14,279m ₹15,818m - 10% ₹4,113m ₹3,428m ₹4,886m 20% - 16% ₹7,541m ₹9,711m - 22% GROSS MARGINS 55.9% 49.5% 61.3% 630 bps - 540 bps 52.8% 61.4% - 860 bps ₹10m - ₹468m ₹1,

  4. Slide 4: Performance Overview

    Performance Overview Key Updates Regulated Markets Regulated Markets US Market Q2FY22 Q1FY22 Q2FY21 QoQ% YoY% H1FY22 H1FY21 YoY% • US revenues at $34m for Q2FY22, US contributed 34% of consolidated revenues in Q2FY22 • Demand continued to be impacted by Covid-19 related headwinds US 2,502 3,016 4,04

  5. Slide 5: Business Highlights

    Business Highlights

  6. Slide 6: US business continued to witness headwinds, growth to resume starting Q3FY22

    US business continued to witness headwinds, growth to resume starting Q3FY22 US Revenues - Quarterly Trend (₹/$M) Business Updates Significant price • Revenues from the US for Q2FY22 stood at ₹2,502 ($34m), down 38% YoY, erosion impacts representing 34% of consolidated revenues for Q2FY22 $53 $58 $5

  7. Slide 7: Chestnut Ridge transaction achieves completion

    Chestnut Ridge transaction achieves completion Transaction Update Strategic Outcomes Key Priorities • Acquisition strengthens Strides’ portfolio, front-end presence and local manufacturing capability for the US • The acquisition more than doubles the approved ANDA • Strides welcomes on board the exp

  8. Slide 8: Robust portfolio in place to drive growth for the US business

    Robust portfolio in place to drive growth for the US business Addressable Strides Endo Combined Dosage Format Market Size Portfolio Portfolio Portfolio US$ m Portfolio Highlights • Combined portfolio of 273 ANDA’s spread across multiple dosage Oral Solids ER 12 12 24 2,717 format • Acquired portfoli

  9. Slide 9: Bounce back in the other regulated markets with growth across key markets

    Bounce back in the other regulated markets with growth across key markets Other Regulated Markets Revenues - Quarterly Trend (₹/$M) Business Updates Covid related supply • Revenues from other regulated markets for Q2FY22 stood at ₹2,825m $40 disruptions ($38m), up 27% QoQ and 18% YoY $37 $38 $35 $31

  10. Slide 10: Emerging markets business continues its growth momentum with a 32% YoY growth

    Emerging markets business continues its growth momentum with a 32% YoY growth Emerging Market Revenues - Quarterly Trend (₹/$M) Business Updates • Revenues from emerging markets for Q2FY22 stood at ₹2,033m ($28m), up 22% QoQ and up 32% YoY $29 $28 $23 • Emerging markets business represented 28% of c

  11. Slide 11: Financial Performance

    Financial Performance

  12. Slide 12: Key P&L Highlights – Q2 and H1FY22

    Key P&L Highlights – Q2 and H1FY22 Income statement (₹m) Particulars Q2 FY22 Q1 FY22 Q2 FY21 QoQ YoY H1 FY22 H1 FY21 YoY Revenues 7,360 6,919 7,971 6% -8% 14,279 15,818 -10% EBITDA 10 -468 1,656 101% -100% -458 3,234 -114% EBITDA % 0.1% -6.8% 20.8% 690 bps -2070 bps -3.2% 20.4% Adj PAT1 -847 -1,169

  13. Slide 13: Net debt and Investments

    Net debt and Investments Pharma Net Debt Investments in CHC & Biotech Total Net Debt As at June 2021 As at June 2021 As at June 2021 ₹ 7,530m ₹ 6,886m ₹ 14,416m As at September 2021 As at September 2021 As at September 2021 ₹ 9,301m ₹ 6,937m ₹ 16,238m Change over June 2021 Change over June 2021 Chan

  14. Slide 14: Q2 and H1FY22 Earnings Call invitation

    Strides Pharma Science Ltd – Q2 and H1FY22 Earnings Call Pre-register and join without operator CLICK HERE invites you to interact with the senior management on Q2 and H1FY22 Join through an operator using dial in WEDNESDAY, NOVEMBER 10, 2021 numbers 4:00pm IST / 11:30am BST / 06:30am EDT / 06:30pm

  15. Slide 15: Thank You

    Thank You Strides Pharma Science Limited CIN: L24230MH1990PLC057062 CORPORATE OFFICE 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703, India Tel.: +91 22 2789 2924/2789 3199 Email: corpcomm@strides.com Website: www.strides.com CIN: L24230MH1990PLC057062 REGISTERED OFFICE Bannerghatta Road, Be

  16. Slide 16: An integrated biologics and vaccine player in the making

    An integrated biologics and vaccine player in the making Stelis Biopharma Limited | November 10, 2021

  17. Slide 17: Recap: Stelis is a vertically integrated biopharma and vaccine company ready to expand horizons

    z Recap: Stelis is a vertically integrated biopharma and vaccine company ready to expand horizons Large Scale Infrastructure One Stop Capabilities Integrated vaccine suite ▸ 3 World class facilities with ▸ One-stop shop solution from cell ▸ Dedicated vaccine facility to cater ~600,000 Square feet R&

  18. Slide 18: Updates on Q2FY22 Performance

    Updates on Q2FY22 Performance 3 operating businesses are tracking to the plan albeit delayed facility inspections due to travel restrictions

  19. Slide 19: The CDMO business is on track to achieve operational break even in FY22

    z The CDMO business is on track to achieve operational break even in FY22 • New orders received for the drug product facility, continued traction for cartridges, high speed vial fill-finish and lyophilized vials Current Business and Orderbook • Completed large scale batches(1000L) for microbial drug

  20. Slide 20: Since the outbreak of Covid-19, Stelis has expanded its scope to manufacture vaccines at large scale

    z Since the outbreak of Covid-19, Stelis has expanded its scope to manufacture vaccines at large scale Update on Sputnik Vaccine In its commitment to fight against Covid-19, Stelis rose to the challenge and planned its foray into vaccines in March 2021 • First component of the Sputnik vaccine has be

  21. Slide 21: In <180 days, our team is ready to produce 720 million vaccine shots per year

    IN <180 DAYS, OUR TEAM IS READY TO PRODUCE 720 MILLION VACCINE SHOTS PER YEAR AND CAN EXPAND TO 1 BILLION ANNUAL DOSES CAPACITY

  22. Slide 22: Our biosimilar products are tracking to plan with first insulin analog completing India CT trials

    z Our biosimilar products are tracking to plan with first insulin analog completing India CT trials Development Molecule Market Size ($b) Indication Latest Update Stage Filed in EU/ STLP001 • EU file for MAA under review, on track to received approval by ~2 Osteoporosis Phase 1 ready for (Rh- Teripa

  23. Slide 23: Thank you

    Thank you For details, please visit www.stelisbiosource.com Stelis Biopharma Limited (Formerly Stelis Biopharma Private Limited) tar 1 Building, Opp. IIM Bangalore, Bilekahalli, Banngerghatta Road, Bangalore – 560 076, India Tel: +91 80 6784 0738 CIN: U74140KA2007PLC043095 For business and investor

Strides Pharma Science — Q2 FY2022 Earnings Presentation on 6ix